Long-term outcome of otherwise healthy individuals with incidentally discovered borderline, thrombocytopenia

被引:67
作者
Stasi, R [1 ]
Amadori, S
Osborn, J
Newland, AC
Provan, D
机构
[1] Osped Regina Apostolorum, Dept Med Sci, Rome, Italy
[2] Univ Roma Tor Vergata, Dept Hematol, Rome, Italy
[3] Univ Roma La Sapienza, Dept Publ Hlth Sci, Rome, Italy
[4] St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, London, England
关键词
D O I
10.1371/journal.pmed.0030024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown. Methods and Findings In a prospective study conducted between August 1992 and December 2002, 260 apparently healthy individuals with incidentally discovered platelet counts between 100 X 10(9)/l and 150 X 10(9)/l were monitored for 6 mo to determine whether their condition persisted. The monitoring period was completed in 217 cases, of whom 191 (88%) maintained stable platelet counts. These 191 individuals were included in a long-term follow-up study to gain knowledge of their natural history. With a median time of observation of 64 mo, the thrombocytopenia resolved spontaneously or persisted with no other disorders becoming apparent in 64% of cases. The most frequent event during the study period was the subsequent development of an autoimmune disease. The 10-y probability of developing idiopathic thrombocytopenic purpura (ITP), as defined by platelet counts persistently below 100 X 10(9)/l, was 6.9% (95% confidence interval [CI]: 4.0%-12.0%). The 10-y probability of developing autoimmune disorders other than ITP was 12.0% (95% CI: 6.9%-20.8%). Most of the cases (85%) of autoimmune disease occurred in women. Conclusions Healthy individuals with a sustained platelet count between 100 X 10(9)/l and 150 X 10(9)/l have a 10-y probability of developing autoimmune disorders of 12%. Further investigation is required to establish whether this risk is higher than in the general population and whether an intensive follow-up results in an improvement of prognosis.
引用
收藏
页码:388 / 394
页数:7
相关论文
共 26 条
[1]   Development of autoantibodies before the clinical onset of systemic lupus erythematosus [J].
Arbuckle, MR ;
McClain, MT ;
Rubertone, MV ;
Scofield, RH ;
Dennis, GJ ;
James, JA ;
Harley, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) :1526-1533
[2]   ESTIMATES OF ABSOLUTE CAUSE-SPECIFIC RISK IN COHORT STUDIES [J].
BENICHOU, J ;
GAIL, MH .
BIOMETRICS, 1990, 46 (03) :813-826
[3]   The determination of a reference range for new platelet parameters produced by the Bayer ADVIA™ 120 full blood count analyser [J].
Brummitt, DR ;
Barker, HF .
CLINICAL AND LABORATORY HAEMATOLOGY, 2000, 22 (02) :103-107
[4]  
Buckley MF, 2000, THROMB HAEMOSTASIS, V83, P480
[5]  
Cheng Calvino Ka-Wing, 2004, Lab Hematol, V10, P42, DOI 10.1532/LH96.04010
[6]  
Chuang-Stein C, 1997, Stat Methods Med Res, V6, P115, DOI 10.1191/096228097671068522
[7]   AUTOIMMUNE THROMBOCYTOPENIA PURPURA AND HASHIMOTOS THYROIDITIS [J].
CRABTREE, GR ;
LEE, JC ;
CORNWELL, GG .
ANNALS OF INTERNAL MEDICINE, 1975, 83 (03) :371-372
[8]   Seasonal changes in platelets, fibrinogen and factor VII in elderly people [J].
Crawford, VLS ;
McNerlan, SE ;
Stout, RW .
AGE AND AGEING, 2003, 32 (06) :661-665
[9]   Breast cancer associated with idiopathic thrombocytopenic purpura -: A single center series of 10 cases [J].
de Latour, RP ;
Des Guetz, G ;
Laurence, VR ;
Palangié, T ;
Pierga, JY ;
Diéras, V ;
Jouve, M ;
Extra, JM ;
Pouillart, P ;
Decaudin, D .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04) :333-336
[10]   The incidence of idiopathic thrombocytopenic purpura in adults increases with age [J].
Frederiksen, H ;
Schmidt, K .
BLOOD, 1999, 94 (03) :909-913